This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 12 studies, archived under the term: "dopamine agents"

Click here to filter this large number of results.

Early-stage cognitive impairment in Parkinson’s disease and the influence of dopamine replacement therapy

Background and Purpose: The aim of this study was to establish the cognitive profile of newly diagnosed untreated (de novo) patients with Parkinson’s disease (PD) and more advanced, treated patients, and to determine the effects of dopamine (DA) replacement therapy.; Methods: A cohort of 23 de novo patients, 55 mild to moderately advanced, medicated PD […]

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease

We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from […]

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease

To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer’s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil […]

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT

Background: Alzheimer’s disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia […]

Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer’s disease in Spain (MEMORY study)

Aim: Memantine is the most recently introduced therapy for the treatment of moderately severe to severe Alzheimer’s disease. The aim of this study was to evaluate safety and effectiveness of memantine under normal clinical practice in patients with moderately severe to severe Alzheimer’s disease. Additionally, we assessed the usual prescription guidelines for memantine.; Patients and […]

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia

Objective: Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on […]

Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine

Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare […]

An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration

There are currently no Food and Drug Administration-approved treatments for frontotemporal lobar degeneration (FTLD). The objectives of this study were to explore the tolerability of memantine treatment in FTLD and to monitor for possible effects on behavior, cognition, and function. Forty-three individuals who met clinical criteria for FTLD [21 with frontotemporal dementia (FTD), 13 with […]

Memantine for AIDS dementia complex: open-label report of ACTG 301

Objective: To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment.; Background: The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infected participants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase.; Method: Participants […]

Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria

We conducted an open, 16-week study on the efficacy of memantine on behavioral disturbances and psychotic symptoms in moderate to moderately severe Alzheimer s disease in daily routine. Fifty-three patients of 20 outpatient centers in Austria were recruited. The Neuropsychiatric Inventory (NPI) was defined as main outcome measure. After 16 weeks the total NPI score […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: